Scynexis Inc (SCYX)

$0.77 0.00 (N/A)
Market Cap 32.28M
Revenue (ttm) 3.75M
Net Income (ttm) -21.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -567.73%
Debt to Equity Ratio 0.00
Volume 268,300
Avg Vol 436,610
Day's Range N/A - N/A
Shares Out 41.93M
Stochastic %K 13%
Beta 1.68
Analysts Strong Sell
Price Target $4.67

Company Profile

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to t...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 201 884 5485
Address:
1 Evertrust Plaza, 13th Floor, Jersey City, United States
Danny_vdw74
Danny_vdw74 Oct. 24 at 3:38 PM
$BURU $VIVK $SCYX NEWS OUT
1 · Reply
Danny_vdw74
Danny_vdw74 Oct. 24 at 3:33 PM
$SCYX
1 · Reply
LemuelPitkin
LemuelPitkin Oct. 24 at 2:18 PM
$SCYX so many of the smarty pants people here have overlooked the significance of Luke Miels taking the helm of GSK. Why wouldn't you think that's significant? Do you know why he's important? I believe we are going to see a significant marketing push around Brexafemme within the first half of 2026. The preparations for this are likely underway already. This is going to be the central focus of GSK because it's a safer and more effective alternative to oral azole treatment which are the current standard of care. If I'm wrong, then a massive big Pharma company chaka block full of medical knowledge and expertise spent and wasted hundreds of millions of dollars for absolutely no reason.
0 · Reply
Teflon600
Teflon600 Oct. 24 at 2:11 PM
$SCYX Undervalued, I’m in.
0 · Reply
LemuelPitkin
LemuelPitkin Oct. 24 at 1:23 PM
$SCYX the spammers here have to be blocked and banned. There's a little more of this crap everyday.
0 · Reply
Laurapicksright
Laurapicksright Oct. 23 at 8:52 PM
$INV Hidden gem with U.S. Department of Energy ARPA-E COOLERCHIPS project, validating technology leadership in next-generation cooling and massive $NVDA let’s break $4 this timeeee 😍😍 next $INTC $AMD $SCYX
0 · Reply
Pommy1
Pommy1 Oct. 23 at 5:24 PM
$SCYX hahaha
0 · Reply
Laurapicksright
Laurapicksright Oct. 23 at 4:04 PM
$OPTT Trump about to make an announcement on battling cartels in the ocean this ticker is helping catch smugglers can bounce over $1 😍 watching $NVDA $SCYX $MSAI $BYND
0 · Reply
Danny_vdw74
Danny_vdw74 Oct. 23 at 3:43 PM
$IVF $SCYX. BURN THE WALL
0 · Reply
Chuckyboss1
Chuckyboss1 Oct. 23 at 12:15 PM
$SCNX $SCYX this will be the next high flyer here lots in the works they have a liquid formula drug only one on the market and a opiate reversal drug that saves life’s Wall Street bets will get hold oh this on soon volume will come in
0 · Reply
Latest News on SCYX
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

Oct 15, 2025, 8:00 AM EDT - 10 days ago

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Sep 4, 2025, 8:30 AM EDT - 7 weeks ago

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 2 months ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025, 8:30 AM EDT - 5 months ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 5:08 PM EDT - 8 months ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Oct 3, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 30, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 9, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Scynexis: Update Following Restructuring Of GSK Deal

Apr 2, 2024, 10:04 AM EDT - 1 year ago

Scynexis: Update Following Restructuring Of GSK Deal

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 4:01 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 29, 2024, 5:15 PM EST - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 8, 2024, 4:00 AM EST - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 5, 2024, 8:30 AM EST - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 4, 2024, 7:00 AM EST - 1 year ago

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

Dec 29, 2023, 4:00 AM EST - 1 year ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 28, 2023, 9:00 AM EST - 1 year ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 22, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 21, 2023, 8:00 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 19, 2023, 5:30 AM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

Dec 18, 2023, 6:46 PM EST - 2 years ago

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 18, 2023, 6:15 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 13, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 8, 2023, 5:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 6, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 4, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 1, 2023, 6:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 30, 2023, 8:30 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 29, 2023, 7:50 PM EST - 2 years ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 22, 2023, 11:45 PM EST - 2 years ago

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 21, 2023, 7:00 AM EST - 2 years ago

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 19, 2023, 11:45 PM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 17, 2023, 11:15 AM EST - 2 years ago

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc.

Nov 15, 2023, 1:15 PM EST - 2 years ago

SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc.

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 5:17 PM EST - 2 years ago

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Oct 24, 2023, 8:00 AM EDT - 2 years ago

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Danny_vdw74
Danny_vdw74 Oct. 24 at 3:38 PM
$BURU $VIVK $SCYX NEWS OUT
1 · Reply
Danny_vdw74
Danny_vdw74 Oct. 24 at 3:33 PM
$SCYX
1 · Reply
LemuelPitkin
LemuelPitkin Oct. 24 at 2:18 PM
$SCYX so many of the smarty pants people here have overlooked the significance of Luke Miels taking the helm of GSK. Why wouldn't you think that's significant? Do you know why he's important? I believe we are going to see a significant marketing push around Brexafemme within the first half of 2026. The preparations for this are likely underway already. This is going to be the central focus of GSK because it's a safer and more effective alternative to oral azole treatment which are the current standard of care. If I'm wrong, then a massive big Pharma company chaka block full of medical knowledge and expertise spent and wasted hundreds of millions of dollars for absolutely no reason.
0 · Reply
Teflon600
Teflon600 Oct. 24 at 2:11 PM
$SCYX Undervalued, I’m in.
0 · Reply
LemuelPitkin
LemuelPitkin Oct. 24 at 1:23 PM
$SCYX the spammers here have to be blocked and banned. There's a little more of this crap everyday.
0 · Reply
Laurapicksright
Laurapicksright Oct. 23 at 8:52 PM
$INV Hidden gem with U.S. Department of Energy ARPA-E COOLERCHIPS project, validating technology leadership in next-generation cooling and massive $NVDA let’s break $4 this timeeee 😍😍 next $INTC $AMD $SCYX
0 · Reply
Pommy1
Pommy1 Oct. 23 at 5:24 PM
$SCYX hahaha
0 · Reply
Laurapicksright
Laurapicksright Oct. 23 at 4:04 PM
$OPTT Trump about to make an announcement on battling cartels in the ocean this ticker is helping catch smugglers can bounce over $1 😍 watching $NVDA $SCYX $MSAI $BYND
0 · Reply
Danny_vdw74
Danny_vdw74 Oct. 23 at 3:43 PM
$IVF $SCYX. BURN THE WALL
0 · Reply
Chuckyboss1
Chuckyboss1 Oct. 23 at 12:15 PM
$SCNX $SCYX this will be the next high flyer here lots in the works they have a liquid formula drug only one on the market and a opiate reversal drug that saves life’s Wall Street bets will get hold oh this on soon volume will come in
0 · Reply
Chuckyboss1
Chuckyboss1 Oct. 23 at 11:55 AM
$SCYX this will be the next high flyer here lots in the works they have a liquid formula drug only one on the market and a opiate reversal drug that saves life’s Wall Street bets will get hold oh this on soon volume will come in
0 · Reply
Danny_vdw74
Danny_vdw74 Oct. 22 at 8:01 PM
$BENF $SCYX SYN100 23/10/25
0 · Reply
Pommy1
Pommy1 Oct. 22 at 4:52 PM
$SCYX I have started loading slowly with small numbers just don’t want to go crazy like 2 yrs back.hope gsk but this co
0 · Reply
Pommy1
Pommy1 Oct. 22 at 3:37 PM
$SCYX they should sell the co if they get chance
0 · Reply
Chuckyboss1
Chuckyboss1 Oct. 22 at 3:02 PM
$SCYX 2 approved drugs lots of interest here wall start bets and discord scanners will pick this up volume coming in managment will do the right thing
1 · Reply
Sncxhakaa
Sncxhakaa Oct. 21 at 6:53 PM
$SCYX
0 · Reply
DestinyNeo
DestinyNeo Oct. 21 at 6:45 PM
$SCYX 👌👌
0 · Reply
XZeroDelta
XZeroDelta Oct. 21 at 12:14 PM
$SCYX The CEO David Angulo bought MORE shares. My hands are harder than diamonds in Pluto.
0 · Reply
pjinvestmentco
pjinvestmentco Oct. 17 at 7:50 PM
$SCYX 75 cents but David and the gang bought themselves 2 to 3 years of salary
0 · Reply
LemuelPitkin
LemuelPitkin Oct. 16 at 11:42 PM
$SCYX Key to sustained stock rise will be the return of Brexafemme, its rising sales, and most importantly, growing royalty payments. One-Time payments for milestones accomplished is nice, but real progress involves the rubber hitting the road, sales.
2 · Reply
Laurapicksright
Laurapicksright Oct. 16 at 1:33 PM
$VNRX Here we goooooo massive insider addding gap up here off $MIRA $WHWK $CSAI $SCYX 😍😍
0 · Reply
Limmy_sg
Limmy_sg Oct. 16 at 10:03 AM
$SCYX correct me if I am wrong . There is still a hansoh milestone payment coming soon upon commercialisation? Some sources mentioned $40MIL
2 · Reply